Prana Biotechnology (PRAN) Secures European and U.S. Patents for Pharmaceutical Compounds
Prana Biotechnology was established to commercialize research into Alzheimer’s disease and other major age-related neurodegenerative disorders. In line with this objective, the company yesterday announced it has received key PBT2 patents in Europe and the United States for select pharmaceutical compositions. “The grant and extension of PBT2 patent rights in the United States together with securing European patent rights marks a critical milestone in our commercialization plans, offering opportunity in both Huntington’s disease and Alzheimer’s disease,” Geoffrey Kempler, Prana’s executive chairman stated in the press release. The U.S. Patent and Trademark Office (USPTO) granted Prana a composition of matter patent…